AI Drug Hunters Could Give Big Pharma a Run for Its Money
DeepMind, the artificial-intelligence arm of Google’s parent Alphabet Inc., could transform how drugmakers discover and develop new medicines and put pressure on the world’s biggest pharma companies.
In December, at the CASP13 meeting in Mexico, DeepMind beat biologists at predicting the shapes of proteins, the basic building blocks of disease. This achievement has serious implications, because a tool that can accurately model protein structures could speed up the development of new drugs.